Distribution of Human Immunodeficiency Virus and Human T-Leukemia Virus Co-infection in Bahia, Brazil

Human Immunodeficiency Virus (HIV) and Human T-Leukemia Virus (HTLV) are retroviruses that share similar routes of transmission. In Brazil, the prevalence of HIV and HTLV varies according to geographic region. The state of Bahia, located in the Northeast region, is considered endemic for both retroviruses. The present study aimed to characterize the frequency of HIV/HTLV coinfection and evaluate the geographic distribution of coinfection throughout the state. This cross-sectional study was conducted at the state's Central Laboratory of Public Health (LACEN-BA) and included all samples from 2004 to 2013 submitted to serological testing for anti-HIV and anti-HTLV-1/2, screened by chemiluminescence/ELISA and confirmed by Western blot. Infection rates are expressed as the number of infected individuals per 100,000 inhabitants from each municipality. A total of 129,158 samples originating from 358/417 (85.8%) municipalities in Bahia were evaluated. HTLV was detected in 2.4% of the HIV-positive samples (n = 42) compared to 0.5% of those with negative HIV serology (n = 677) (OR: 4.65; CI: 3.39–6.37). HIV/HTLV coinfection was more frequent in women (69.0%); the median age of coinfected individuals was 47.2 years [interquartile range (IQR): 41.6–55.4 years]. In the 14/417 (3.4%) municipalities where at least one case of HIV/HTLV coinfection was detected, the overall HTLV coinfection rate in HIV-positive samples was 0.25 (range: 0.17–13.84) per 100,000 inhabitants. Most cases of HIV/HTLV-1 coinfection (21/37, 57%) were concentrated in the municipality of Salvador. Isolated instances (one or two cases) of HIV/HTLV-1 coinfection were distributed across municipalities known to be endemic for HTLV infection.

Download Full-text

A High Prevalence Rate of a Positive Screen for Cognitive Impairment in Patients With Human Immunodeficiency Virus Attending an Irish Clinic

Open Forum Infectious Diseases ◽

10.1093/ofid/ofw242 ◽

2016 ◽

Vol 4 (1) ◽

Cited By ~ 2

Author(s):

Patricia H. McNamara ◽

Robert Coen ◽

Janice Redmond ◽

Colin P. Doherty ◽

Colm Bergin

Keyword(s):

Human Immunodeficiency Virus ◽

Cognitive Impairment ◽

Large Scale ◽

Screening Program ◽

Cross Sectional Study ◽

Hiv Positive ◽

Study Cohort ◽

Cross Sectional ◽

Positive Screen ◽

Immunodeficiency Virus

Abstract Background Human immunodeficiency virus (HIV)-associated neurocognitive disorders occurs in 20%–50% of HIV-positive patients. We undertook this study to assess the prevalence of a positive screen for cognitive impairment in the clinic population at our institution and to demonstrate the feasibility of implementing a screening program in routine clinical encounters. Methods This was a cross-sectional study, and patients were recruited prospectively between December 2010 and February 2013. Inclusion criteria were as follows: patients were HIV positive, over the age of 18, capable of giving informed consent, and had sufficient ability to communicate in English. Patients were screened for cognitive impairment using the Brief Neurocognitive Screen. Results A total of 604 patients were recruited, and 51.5% had a positive screen for cognitive impairment. The majority of the study cohort were male (78.8%), mean age was 40.9 (standard deviation, 10.2) years, 70.9% were Irish, the most common mode of transmission was men who have sex with men (49.3%), 83% were on antiretroviral therapy, and 88.7% were virally suppressed. Logistic regression showed that the main factors predictive of a positive screen for cognitive impairment were the endorsement of cognitive symptoms (P = .024), being born in Africa (P < .000001), the use of benzodiazepines (P = .00341), being unemployed (P = .008), and consumption of more than 40 units of alcohol weekly (P = .035). There was a positive screen for depression in 9.1% and a positive screen for anxiety in 24.5%. Conclusions The study highlights the necessity for a structured, prospective, large-scale screening program for cognitive impairment across countries with limited resources and demonstrates the feasibility of easily implementing this with minimal training.

Download Full-text

Human immunodeficiency virus (HIV) type 1 genetic diversity in HIV positive individuals on antiretroviral therapy in a cross sectional study conducted in Teso, Western Kenya

Pan African Medical Journal ◽

10.11604/pamj.2021.38.335.26357 ◽

2021 ◽

Vol 38 ◽

Author(s):

Maureen Adhiambo ◽

Olipher Makwaga ◽

Ferdinard Adungo ◽

Humphrey Kimani ◽

David Hunges Mulama ◽

...

Keyword(s):

Genetic Diversity ◽

Human Immunodeficiency Virus ◽

Cross Sectional Study ◽

Hiv Positive ◽

Sectional Study ◽

Cross Sectional ◽

Western Kenya ◽

Immunodeficiency Virus ◽

Hiv Type 1

Download Full-text

Hypertension among human immunodeficiency virus infected patients on treatment at Parirenyatwa Hospital: A descriptive study

African Journal of Primary Health Care & Family Medicine ◽

10.4102/phcfm.v11i1.1974 ◽

2019 ◽

Vol 11 (1) ◽

Cited By ~ 1

Author(s):

Rumbidzai Chireshe ◽

Keshena Naidoo ◽

Rudo Nyamakura

Keyword(s):

Human Immunodeficiency Virus ◽

Prolonged Exposure ◽

Cross Sectional Study ◽

Sub Saharan Africa ◽

Hiv Positive ◽

Cross Sectional ◽

Highly Active ◽

Age Related ◽

Immunodeficiency Virus ◽

Associated Risk Factors

Background: Since the roll-out of antiretroviral therapy (ART) in sub-Saharan Africa (sSA) in the early 2000s, the life expectancy of people infected with the human immunodeficiency virus (HIV) has increased. However, the gains made in reducing mortality from HIV-related complications have been mitigated by the emergence of age-related chronic non-communicable diseases (NCDs), such as hypertension. Protease inhibitors (PIs), and prolonged exposure to highly active ART (HAART) have been implicated in the development of hypertension in HIV-positive people.Aim: To investigate the prevalence of hypertension and its associated risk factors among HIV-positive patients receiving ART.Setting: The study was carried out at an urban-based clinic that provides HAART and primary care to HIV-positive people in Harare, Zimbabwe.Methods: A descriptive, cross-sectional study was conducted among non-pregnant adults on HAART attending the clinic between July and August 2018.Results: We studied 600 HIV-positive adult patients, of which 56% were women. The prevalence rate of hypertension was 29.9%. Of the participants in the hypertensive group, 11.2% were not previously diagnosed or on treatment. Factors associated with hypertension were advanced age, use of HAART for longer than 10 years, being overweight, a family history of hypertension and smoking. There was a 68.8% prevalence of body mass index greater than 25 kg/m2 among all participants.Conclusion: High hypertension prevalence was recorded. Hypertension was not associated with gender or use of PI regimens but being overweight was highly prevalent. Greater vigilance and integration of resources is required in the overall treatment and monitoring of HIV-positive patients for co-morbidities.

Download Full-text

Coinfection of Hepatitis B and C with Human Immunodeficiency Virus in Hemophilia: A Cross Sectional Study

Journal of Advances in Medicine and Medical Research ◽

10.9734/jammr/2020/v32i1730641 ◽

2020 ◽

pp. 45-52

Author(s):

T. S. Espósito ◽

T. M. M. Paz ◽

L. O. W. Rodrigues ◽

A. C. A. Santos ◽

R. D. M. Almeida ◽

...

Keyword(s):

Human Immunodeficiency Virus ◽

Hepatitis C ◽

Hepatitis B ◽

Hemophilia A ◽

Cross Sectional Study ◽

Assay Method ◽

Hiv Positive ◽

Sectional Study ◽

Cross Sectional ◽

Immunodeficiency Virus

Aims: To identify coinfection by Hepatitis B (HBV), Hepatitis C (HCV) and Human immunodeficiency virus (HIV) in Hemophiliacs. Methodology: We included 107 hemophiliacs. For the current analysis, age, type, severity of Hemophilia and serum profile for Hepatitis B, C and HIV were included. The serological tests performed for Hepatitis and HIV were carried out using the enzyme-linked immunosorbent assay method (ELISA) and the confirmatory tests for HIV and HCV were done by the Western Blot and Polymerase Chain Reaction (PCR). The results of positive and negative serology were compared using the Mann-Whitney test using the Fundação Hemominas reproducibility map of serological reactions, through the CUT-off of each test. Study Design: A cross-sectional study was carried out on hemophilics to asses the prevalence of infections diseases transmitted by transfusion. Place and Duration of Study: Department of Hematology, public service on Coagulopathies at Fundação Hemominas Juiz de Fora Brazil, between January 2008 to December 2018. Results: The average age was 32.77 years with standard deviation (SD)= 16.8 years. In regard to classification, 57.65% of patients with Hemophilia A were severe, and 57% of patients with Hemophilia B were moderate. Laboratory results demonstrated that 24.3% of the patients were HBV positive, and 40.2% were HCV positive, with 21.42% positive by PCR. The prevalence of HIV positive was 11.2%. In general analysis, 44.82% had at least one type of viral infection and 23.4% presented coinfections. HIV positive patients were all positive for HCV (11.2%) and 7.5% of patients were infected by HIV, HCV and HBV. The coexistence of hepatitis C and HIV was statistically relevant with (P = .001), considering the year of birth, most patients with HCV and HIV were born before 1980s (P = .001). Conclusions: Infections by HBV, HCV and HIV are late complications in patients that received blood products before 1990s. Infection by a viral agent and the year of birth has a direct association, due to the standardization and implantation of tests for HIV and HCV in the 80s and 90s.

Download Full-text

Serological prevalence of rubella, cytomegalovirus, herpes simplex virus, treponema pallidum and human immunodeficiency virus in antenatal women with bad obstetric history – A cross sectional study

MedPulse International Journal of Microbiology ◽

10.26611/10081125 ◽

2019 ◽

Vol 11 (2) ◽

pp. 28-34

Author(s):

Shama Taj K R ◽

Keyword(s):

Human Immunodeficiency Virus ◽

Herpes Simplex Virus ◽

Herpes Simplex ◽

Treponema Pallidum ◽

Cross Sectional Study ◽

Sectional Study ◽

Cross Sectional ◽

Obstetric History ◽

Immunodeficiency Virus ◽

Simplex Virus

Download Full-text

SAT0078 SAFETY OF LOW DOSE METHOTREXATE (MTX) IN HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2020-eular.2968 ◽

2020 ◽

Vol 79 (Suppl 1) ◽

pp. 974.2-974

Author(s):

A. Gunay ◽

A. Davidson ◽

I. Colmegna ◽

D. Lacaille ◽

H. Loewen ◽

...

Keyword(s):

Human Immunodeficiency Virus ◽

Adverse Events ◽

Low Dose ◽

Opportunistic Infections ◽

Case Reports ◽

Cross Sectional Study ◽

Study Quality ◽

Sectional Study ◽

Cross Sectional ◽

Immunodeficiency Virus

Background:Increased awareness of the efficacy of MTX in rheumatic disease is leading to more MTX use in patients from HIV endemic areas. While HIV related immunosuppression may contribute to improvement of some rheumatic diseases, immune reconstitution from highly active antiretroviral therapy (HAART) may lead to exacerbation or presentation of autoimmune disorders for which MTX therapy may be warranted. Most management guidelines for rheumatic disease do not address MTX use in the context of HIV.Objectives:To systematically review the published literature on the safety of using MTX ≤30 mg per week in HIV.Methods:We searched CINAHL, Embase, Global, MEDLINE and World of Science databases (Jan 1990 to May 2018) for terms including ‘methotrexate’ and ‘human immunodeficiency virus’. We also searched citations from review articles. Titles, abstracts or full manuscripts were screened independently by 2 reviewers to identify studies reporting HIV in patients taking MTX. Study quality was assessed using the McGill Mixed Methods Appraisal Tool (MMAT). Data was extracted on MTX and HIV adverse events (MTX toxicity, HIV viral load, CD4 count). Descriptive summaries are presented for studies providing outcomes in patients taking MTX ≤30 mg per week.Results:After removing duplicates and studies not meeting criteria or not providing sufficient information, 42 of the 2714 identified reports were included (1 clinical trial, 2 cohort, 1 cross-sectional study, 38 case reports/case series). Most reports (81%) originated from USA or Europe. Study quality was generally good with most studies fulfilling 50-100% of MMAT criteria. The randomized controlled trial (USA) assessing MTX on atherosclerotic disease in HIV showed that adverse events were more common in MTX versus placebo (12.8% vs 5.6%, p non-inferiority <0.05) and included infection, transient CD4 and CD8 drop, pulmonary toxicity, and death (1 attributed to MTX/HIV, 1 unrelated). One cohort study (South Africa) reported 43 RA patients on MTX who acquired HIV. In this cohort, RA generally improved despite only 5 individuals continuing MTX. No data on MTX adverse event rates was reported. One cohort study (USA) reported 13 HIV patients with myositis. One received MTX (with other immunosuppression) without MTX adverse effects but died due to AIDS. A cross-sectional study (France) of 43 HIV pts with autoimmune disease reported one patient on MTX (and other immunosuppression) developed an adverse event (cytopenia) compared to 5/33 patients not on MTX (cytopenia). The 38 case reports/series described 54 individuals with HIV receiving MTX. Of these studies, 27 (describing 42 subjects) reported on MTX adverse events and 35 (describing 46 subjects) reported on HIV adverse events. MTX adverse events developed in 29 subjects (hematologic 13, renal/hepatic 1, opportunistic infections 10, other events 2). HIV adverse events were noted in 23 subjects (Kaposi’s sarcoma 4, CD4 decrease 16, HIV viral titer increase 4). Five deaths were reported (2 infection, 1 infection and wasting, 2 HIV related deaths). Most subjects also received corticosteroids or other immunosuppressants including biologics.Conclusion:There remains limited data on the safety of low dose MTX in HIV. Surveillance for HIV is warranted for individuals on MTX who are at risk for acquiring HIV. Caution and careful monitoring for MTX toxicity, opportunistic infections and HIV state is suggested if MTX is used in the setting of HIV particularly if combined with other immunosuppression.References:[1] Clin Infectious Disease 2019:68[2] J Rheumatology 2014:41[3] Arthritis and Rheumatism 2003:49[4] Medicine 2017:96Acknowledgments :Funding from International League Against RheumatismMcGill University Global Health Scholar AwardsDisclosure of Interests:Alize Gunay: None declared, Anna Davidson: None declared, Ines Colmegna: None declared, Diane Lacaille: None declared, Hal Loewen: None declared, Michele Meltzer: None declared, Yewondwossen Mengistu: None declared, Rosie Scuccimarri: None declared, Zenebe Yirsaw: None declared, Sasha Bernatsky: None declared, Carol Hitchon Grant/research support from: UCB Canada; Pfizer Canada

Download Full-text

Consistent Patterns of Change during the Divergence of Human Immunodeficiency Virus Type 1 Envelope from That of the Inoculated Virus in Simian/Human Immunodeficiency Virus-Infected Macaques

Journal of Virology ◽

10.1128/jvi.80.2.999-1014.2006 ◽

2006 ◽

Vol 80 (2) ◽

pp. 999-1014 ◽

Cited By ~ 50

Author(s):

W.M. Blay ◽

S. Gnanakaran ◽

B. Foley ◽

N. A. Doria-Rose ◽

B. T. Korber ◽

...

Keyword(s):

Human Immunodeficiency Virus ◽

Disulfide Bonds ◽

Neutralizing Antibodies ◽

Outer Region ◽

Synonymous Substitution ◽

Cross Sectional Study ◽

Macaca Nemestrina ◽

Cross Sectional ◽

Immunodeficiency Virus ◽

And Shifts

ABSTRACT We have analyzed changes to proviral Env gp120 sequences and the development of neutralizing antibodies (NAbs) during 1 year of simian/human immunodeficiency virus SHIV-89.6P infection in 11 Macaca nemestrina macaques. Seven macaques had significant env divergence from that of the inoculum, and macaques with greater divergence had higher titers of homologous NAbs. Substitutions in sequons encoding potential N-linked glycosylation sites (PNGs) were among the first to be established, although overall the total number of sequons did not increase significantly. The majority (19 of 23) of PNGs present in the inoculum were conserved in the sequences from all macaques. Statistically significant variations in PNGs occurred in multiple macaques within constrained regions we term “hot spots,” resulting in the selection of sequences more similar to the B consensus. These included additions on V1, the N-terminal side of V4, and the outer region of C2. Complex mutational patterns resulted in convergent PNG shifts in V2 and V5. Charge changes in Env V1V2, resulting in a net acidic charge, and a proline addition in V5 occurred in several macaques. Molecular modeling of the 89.6P sequence showed that the conserved glycans lie on the silent face of Env and that many are proximal to disulfide bonds, while PNG additions and shifts are proximal to the CD4 binding site. Nonsynonymous-to-synonymous substitution ratios suggest that these changes result from selective pressure. This longitudinal and cross-sectional study of mutations in human immunodeficiency virus (HIV) env in the SHIV background provides evidence that there are more constraints on the configuration of the glycan shield than were previously appreciated.

Download Full-text